Gastrointestinal(GI)cancer remains the deadliest cancer in the world.The current standard treatment for GI cancer focuses on 5-fluorouracil-based chemotherapeutic regimens and surgery,and molecular-targeted therapy is...Gastrointestinal(GI)cancer remains the deadliest cancer in the world.The current standard treatment for GI cancer focuses on 5-fluorouracil-based chemotherapeutic regimens and surgery,and molecular-targeted therapy is expected to be a more effective and less toxic therapeutic strategy for GI cancer.There is wellestablished evidence for the use of epidermal growth factor receptor-targeted and vascular endothelial growth factor-targeted antibodies,which should routinely be incorporated into treatment strategies for GI cancer.Other potential therapeutic targets involve the PI3K/AKT pathway,tumor growth factor-βpathway,mesenchymal-epithelial transition pathway,WNT pathway,poly(ADP-ribose)polymerase,and immune checkpoints.Many clinical trials assessing the agents of targeted therapy are underway and have presented promising and thoughtprovoking results.With the development of molecular biology techniques,we can identify more targetable molecular alterations in larger patient populations with GI cancer.Targeting these molecules will allow us to reach the goal of precision medicine and improve the outcomes of patients with GI cancer.展开更多
基金Supported by KAKENHI(Grant-in-Aid for Scientific Research),No.18H02883.
文摘Gastrointestinal(GI)cancer remains the deadliest cancer in the world.The current standard treatment for GI cancer focuses on 5-fluorouracil-based chemotherapeutic regimens and surgery,and molecular-targeted therapy is expected to be a more effective and less toxic therapeutic strategy for GI cancer.There is wellestablished evidence for the use of epidermal growth factor receptor-targeted and vascular endothelial growth factor-targeted antibodies,which should routinely be incorporated into treatment strategies for GI cancer.Other potential therapeutic targets involve the PI3K/AKT pathway,tumor growth factor-βpathway,mesenchymal-epithelial transition pathway,WNT pathway,poly(ADP-ribose)polymerase,and immune checkpoints.Many clinical trials assessing the agents of targeted therapy are underway and have presented promising and thoughtprovoking results.With the development of molecular biology techniques,we can identify more targetable molecular alterations in larger patient populations with GI cancer.Targeting these molecules will allow us to reach the goal of precision medicine and improve the outcomes of patients with GI cancer.
文摘为解决当前常用煤矿氧气检测仪器易受交叉气体干扰且功耗大的问题,基于GD32F303RCT6微控制器和ADN8834热电冷却控制器,设计了一种软启动开关电路控制的垂直腔面发射激光器(Vertical-cavity Surface-emitting Laser,VCSEL)高精度驱动及温控电路。驱动电路中,高频正弦波信号和低频锯齿波信号叠加的二进制数据由微控制器产生,经信号发生电路、电压电流转换电路转化成VCSEL高精度驱动电流信号;温控电路中,设计基于比例积分微分(Proportional Integral Differential,PID)补偿电路和数模转换控制器(Digital to Analog Converter,DAC)目标温度控制电路实现激光器温度自动调节。测试结果表明:驱动电路的电流输出区间为0.680~1.360 mA;锯齿波频率误差小于0.5%,正弦波频率误差小于0.1%;氧气吸收峰扫描精度高达0.07 pm,对应电流扫描精度为0.12μA;温控电路的温度控制精度为±0.012℃。满足了可调谐半导体激光吸收光谱(Tunable Diode Laser Absorption Spectroscopy,TDLAS)煤矿氧气检测应用需求。
